Restricted accessResearch articleFirst published online 2008-5
Vincristine,Doxorubicin,and Cyclophosphamide Alternating with Ifosfamide and Etoposide Regimen for Ewing's Sarcoma and Primitive Neuroectodermal Tumor (PNET) of Bone
The increasing complexity of cancer chemotherapy now requires that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases.
KolbE.A., KushnerB.H., GorlickR.. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol.2003; 21(18): 3423–3430.
2.
KushnerB.H., MeyersP.A.How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol.2001; 19(3): 870–880.
3.
MiserJ.S., KrailoM.D., TarbellN.J.. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide- a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol.2004; 22(14): 2873–2876.
4.
GrierH.E., KrailoM.D., TarbellN.J.. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med.2003; 348(8): 694–701.
TrisselL., ZhangY., CohenM.The stability of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection. Hosp Pharm.2001; 36(7): 740–745.
7.
HeskethP.J., KrisM.G., GrunbergS.M.. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
8.
National Comprehensive Cancer Network. NCCN antiemesis practice guidelines. http://www.nccn.org/. Accessed February 12, 2008.
9.
KrisM.G., HeskethP.J., SomerfieldM.R.. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006; 24(18): 2932–2947.
10.
Multinational Association for Supportive Care in Cancer. Antiemetic Guidelines. 2005. http://www.mascc.org/. Accessed January 15, 2008.
11.
BeckT.M.The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron. Anticancer Drugs.1995; 6(2): 237–242.
12.
MartinM.The severity and pattern of emesis following different cytotoxic agents. Oncology.1996; 53(Suppl 1): 26–31.
13.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
14.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
15.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anti-cancer Drugs.1998; 9(5): 381–385.
16.
de WitR., e BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 85(8): 1099–1101.
17.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
18.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
19.
StillwellT.J., BensonR.C.Jr. Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer.1988; 61(3): 451–457.
SmithT.J., KhatcheressianJ., LymanG.H.. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
22.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology - Myeloid Growth Factors. v.1.2006. http://www.nccn.org/. Accessed February 12, 2008.
23.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
24.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75(3): 397–405.
25.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineo-plastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
26.
MouridsenH.T., LangerS.W., ButerJ.. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol.2007; 18(3): 546–550.
27.
FloydJ., MirzaI., Sachs, PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33(1): 50–67.
28.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
